Welcome To Our Website!SALES DEPT:info@puresynmr.com

ProductsHome>Products

SARMS/Capromorelin -selective androgen receptor modulator

CAS#: 193273-66-4

Product Price: Contact us to get the latest price

Product Specification : 98%

Minmum Order Quantity : >50g

Sample Requirement : Free Sample / Freight Charged / to final agreement

Product No.: PURCAP

Product Introduction

What is (CP-424,391)?

Capromorelin (INN) (developmental code name CP-424,391) is an investigational medication developed by the Pfizer drug company.It functions as a growth hormone secretagogue and ghrelinmimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Initial studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) and growth hormone levels
The drug is being considered for its therapeutic value in aging adults because elderly people have much lower levels of growth hormone and less lean muscle mass, which can result in weakness andfrailty.


How it works?

Capromorelin functions as a growth hormone secretagogue and ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Initial studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) and growth hormone levels.

Dosages and Suggestion

Recommended maximum dose Capromorelin the safety and tolerability up to doses of 22 mg -25mg . It has a half-life of 24 hours a day.

SARMS We offer

AICAR

2627-69-2

acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown

MK2866

841205-47-8

medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.

MK-677

15972-10-0

A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly

LGD-4033

1165910-22-4

pharmacological profile similar to that of enobosarm, Ostarine,MK-2866

GW501516

317318-70-0

For obesity, diabetes, dyslipidemia and cardiovascular disease

Andarine(S4)

401900-40-0

partial agonist, intended mainly for treatment of benign prostatic hypertrophy

SR9009

1379686-30-2

under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice

SR9011

1379686-30-2

For obesity, diabetes, dyslipidemia and cardiovascular disease

RAD140

1182367-47-0

New generation for gaining mass and cutting edges

YK11

366508-78-3

431579-34-9

a SARM and myostatin inhibitor in one

GHRP-2

158861-67-7

Growth Hormone Releasing Peptide-2

GHRP-6

87616-84-0

Growth Hormone Releasing Peptide-6

TB500

107761-42-2

Thymosin beta 4

SM130,686

/

/

Copyright © 2012 SYNMR All Rights Reserved. Design by Baiqi